Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Imaxio Closes EUR 2.9 Million Funding Round

Published: Wednesday, April 18, 2012
Last Updated: Wednesday, April 18, 2012
Bookmark and Share
Funding will enable the clinical development of its IMX313 carrier protein platform for vaccines, and update the marketing authorization application it filed in France.

Imaxio has announces that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

This latest injection of funds will enable Imaxio to speed up its organic growth through two major R&D projects.

The first is the clinical development of its IMX313 vaccine-carrying protein platform, which is designed to improve the efficacy of vaccinations against various diseases in humans (such as tuberculosis, malaria and cancers) as well as in animals.

IMX313 is scheduled to enter clinical development in 2013 and by the end of next year preclinical proof of principle is expected to be established in new indications.

Imaxio is thus seeking to conclude co-development and industrial partnership agreements for IMX313 for the purpose of having its carrier protein technology incorporated in new vaccines.

The second project is the international commercialization of its vaccine against human leptospirosis, Spirolept, which is already marketed in France.

The company wants to complete the update of its marketing authorization application so as to be able to submit additional applications in other European countries starting in 2015.

Although leptospirosis is often benign, the disease can take an acute form and lead to renal failure, or even death, in five to ten per cent of untreated cases.

“We are very pleased with this new investment, which is further confirmation of the confidence that Pradeyrol Developpement has in Imaxio and in the strategy it adopted a year ago,” said Alexandre Le Vert, managing director of Imaxio.

Vert continued, “This is an important stage for the company, allowing us to concentrate on two major R&D projects, and especially the IMX313 carrier protein platform for vaccines. The development of vaccines against some major diseases (including tuberculosis and malaria) is being impeded by the inefficacy of vaccine candidates, which could be overcome by the IMX313 carrier protein.”

“As an historic shareholder, it is important for us to support Imaxio’s development strategy, which it adopted a year ago,” said Doctor Christian Pradeyrol, chairman of Pradeyrol Developpement.

Doctor Pradeyrol continued, “The vaccine market is consistently growing, having increased by 21 per cent between 2006 and 2010, which makes it a very promising sector, especially for Imaxio and its carrier protein technology.”

To support its development, Imaxio also relies on numerous institutional and academic partners, such as the Jenner Institute at Oxford University, Pierre Fabre, the U.S. Department of Agriculture (USDA), the French national influenza research center, and research teams working for Inserm (the French National Institute of Health and Medical Research) and the CNRS (France’s National Scientific Research Center) in Lyon, Clermont-Ferrand, Tours, Toulouse and Paris.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Signs an Option for a License Agreement with DKFZ
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus.
Friday, October 17, 2014
Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
IMX313 has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial.
Monday, September 16, 2013
Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.
Wednesday, September 04, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop Staphylococcus Aureus Vaccine
A consortium has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Wednesday, July 03, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop S. aureus Vaccine
A consortium comprising Imaxio, the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Tuesday, July 02, 2013
Imaxio Acquires Orphan Drug Indicated for a Congenital Metabolic Disease
This acquisition strengthens Imaxio’s pharmaceutical range, which now includes two products sold in France and will finance the development of its vaccine candidates.
Tuesday, January 22, 2013
Imaxio Signs an Option for a License Agreement with Merial
This option agreement confirms the potential of Imaxio’s antigen re-engineering technology to improve human and animal health vaccines.
Tuesday, December 18, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!